Multimeric Fusion Protein Glycoengineering for IgG Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for IgG-mediated disorders and antibody-mediated injury during organ transplantation are limited in efficacy and specificity, and there is a need for innovative approaches to modulate IgG effector functions.
Innovation Solution
The development of a multimeric fusion protein comprising an antibody heavy chain CH2 and CH3 regions fused with catalytic domains of sialyltransferase and galactosyltransferase, which can be administered to treat IgG-mediated disorders and antibody-mediated injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for IgG-mediated disorders, then treatment can be provided, but efficacy and specificity are limited
Solution Approach 1:
The invention changes the chemical parameters of IgG by enzymatically modifying its glycosylation pattern. Specifically, sialyltransferase and galactosyltransferase enzymes are used to add sialic acid and galactose residues to the IgG glycans, respectively. This parameter change in glycosylation structure transforms the biological activity of IgG, enabling it to modulate effector functions with enhanced efficacy and specificity for treating IgG-mediated disorders
2Reliability
If IgG effector functions are modulated through glycosylation engineering, then treatment efficacy improves, but treatment complexity increases
Solution Approach 1:
The invention employs a self-service approach where the therapeutic IgG molecules themselves carry the enzymatic machinery (sialyltransferase and galactosyltransferase domains) required for their own glycosylation modification. This allows the IgG to autonomously modify its own glycan structures in vivo, eliminating the need for complex external enzymatic treatment protocols and reducing overall treatment complexity while maintaining high efficacy
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The multimeric fusion protein effectively modulates IgG effector functions by sialylating and galactosylating glycoproteins, thereby attenuating autoantibody-mediated inflammation and improving treatment outcomes for IgG-mediated disorders and antibody-mediated injury.
Implementation Method 1
the catalytic domain of sialyltransferase catalyzes sialylation of a glycoprotein
Implementation Method 2
the catalytic domain of galactosyltransferase catalyzes galactosylation of a glycoprotein
Data Source
Figure 1A~1C
Figure 1D~1E
Figure 2A~2B
AI summary
This disclosure relates to glycoengineering, and methods of utilizing glycoengineering for various therapeutic purposes.